Alnylam announces preliminary* fourth quarter and full year 2021 global net product revenues and provides additional updates

Cambridge, mass.--(business wire)--alnylam pharmaceuticals, inc. (nasdaq: alny), the leading rnai therapeutics company, today announced its preliminary* fourth quarter and full year 2021 global net product revenues for onpattro, givlaari and oxlumo and provided additional updates on the products' commercial launches. 2021 preliminary commercial and financial performance* onpattro® (patisiran), a commercial-stage rnai therapeutic targeting transthyretin (ttr) for the treatment of polyneuropathy
ALNY Ratings Summary
ALNY Quant Ranking